These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24002428)

  • 1. Managing new oral anticoagulants in the intensive care unit.
    Gass JA; Weeks PA
    Crit Care Nurs Q; 2013; 36(4):390-9. PubMed ID: 24002428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects.
    Yates S; Sarode R
    Curr Opin Hematol; 2013 Nov; 20(6):552-7. PubMed ID: 24104417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.
    Peacock WF
    Hosp Pract (1995); 2014 Oct; 42(4):75-82. PubMed ID: 25502131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.
    Douketis JD
    Curr Pharm Des; 2010; 16(31):3436-41. PubMed ID: 20858185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
    Fenger-Eriksen C; Münster AM; Grove EL
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):651-9. PubMed ID: 24716468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban.
    Moorman ML; Nash JE; Stabi KL
    J Trauma Acute Care Surg; 2014 Sep; 77(3):486-94; quiz 486-94. PubMed ID: 25159255
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
    Wong PC; White A; Luettgen J
    Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory monitoring of the non-vitamin K oral anticoagulants.
    Blann AD; Lip GY
    J Am Coll Cardiol; 2014 Sep; 64(11):1140-2. PubMed ID: 25212649
    [No Abstract]   [Full Text] [Related]  

  • 12. Anticoagulation: a GP primer on the new oral anticoagulants.
    Brieger D
    Aust Fam Physician; 2014 May; 43(5):254-9. PubMed ID: 24791763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advantages and limitations of the new anticoagulants.
    Schulman S
    J Intern Med; 2014 Jan; 275(1):1-11. PubMed ID: 24112453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacodynamic and pharmacokinetic characteristics. Mechanism of action of the new oral anticoagulants].
    Roldán Schilling V; Vicente García V
    Med Clin (Barc); 2012 Oct; 139 Suppl 2():10-2. PubMed ID: 23498066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
    Giorgi MA; Cohen Arazi H; Gonzalez CD; Di Girolamo G
    Expert Opin Pharmacother; 2011 Mar; 12(4):567-77. PubMed ID: 21254865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute management of bleeding in patients on novel oral anticoagulants.
    Siegal DM; Crowther MA
    Eur Heart J; 2013 Feb; 34(7):489-498b. PubMed ID: 23220847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication.
    Sadeghi N; Kahn D; Jeske W; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2013; 19(6):589-99. PubMed ID: 23463187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient management of oral anticoagulation in atrial fibrillation.
    Manning JA
    Crit Care Nurs Clin North Am; 2013 Dec; 25(4):481-7, vi. PubMed ID: 24267284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing new oral anticoagulants in the perioperative and intensive care unit setting.
    Levy JH; Faraoni D; Spring JL; Douketis JD; Samama CM
    Anesthesiology; 2013 Jun; 118(6):1466-74. PubMed ID: 23416382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC; Easton JD; Hankey GJ; Hart RG
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.